-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Mentari Therapeutics with Outperform Rating, Announces Price Target of $33

Benzinga·11/13/2026 13:35:37
Listen to the news
Wedbush analyst Laura Chico initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Outperform rating and announces Price Target of $33.